Work

Clinical and pharmacogenetic risk factors for the development of early adverse reactions when prescribing antipsychotics for the treatment of conduct disorders in boys without intellectual disability

Year: 2026
Type: article
Study design: Observational Study
Abstract: Objectives To identify associations between the DRD2 rs1800497 and HTR2A rs6311/rs6313 genotypes, adjunctive pharmacotherapy and the effectiveness and safety of antipsychotics prescribed for conduct disorders in boys without intellectual disability in first 14 days of treatment. Methods This study included 115 boys aged 7–12 years without intellectual disability hospitalized for conduct disorders and prescribed an antipsychotic. Follow-up lasted 14 days, with examinations at enrollment, day 5 and 14. Effectiveness was assessed with the CGI-S, CGI-I and CGAS scales; safety, using the UKU SERS and SAS scales. All patients were genotyped for DRD2 rs1800497, HTR2A rs6311 and rs6313. A Poisson regression analysis was carried out to identify the most significant risk factors for the development of adverse drug reactions. Results No polymorphism was significantly associated with effectiveness. Physical aggression towards peers before hospitalization was more frequent in DRD2 CT+TT carriers (95.12% vs 64.38%; p=0.0002). No other factors were identified that were significantly associated with the effectiveness of treatment for conduct disorders. Regression analysis revealed that the frequency of complaints about ADRs was predominantly associated with the prescription of mood stabilisers. In particular, the prescription of a mood stabiliser was associated with a higher frequency of complaints regarding ‘Disturbances of the autonomic nervous system’ (ß=3.116; SE = 0.89; p<0.001) and the total number of ADRs (ß =1.001; SE = 0.42; p=0.018). On day 14, the prescription of mood stabilisers was associated with a higher frequency of ‘Mental disturbances’ (ß =2.026; SE = 0.87; p=0.019), ‘disturbances of the autonomic nervous system’ (ß =3.183; SE = 0.89; p<0.001) and the total number of ADRs (ß =2.4; SE = 0.5; p<0.001). Conclusion Adjunctive pharmacotherapy was the strongest risk factor of early adverse reactions to antipsychotics. Pharmacogenetic factors ( DRD2 rs1800497, HTR2A rs6311, rs6313) showed a weak association with the risk of developing adverse reactions; there is a high likelihood of a false-positive result. Further research into pharmacogenetic predictors of antipsychotic safety in children with conduct disorders and without intellectual disability is needed.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
Award: G798225193
OpenAlex ID: W7236668795
FWCI:
Cites: 46
Cited by:
Related to: 10
Parts: 1